Non-interventional Post-authorization Safety Study (PASS) of Patients Treated with Idecabtagene Vicleucel (ide-cel, BB2121) for Multiple Myeloma (MM) in the Postmarketing Setting (BB2121-MM-006)

03/02/2022
02/07/2024
EU PAS number:
EUPAS45152
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

BB2121-MM-006-prot-v1-redacted

English (446.6 KB - PDF) View document
Study results
Study report
Other information